Compare Payoneer Global Inc (PAYO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Zimmer Biomet Holdings Inc — how do they compare? Payoneer Global Inc trades at $7.15 (market cap $2.43B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7× Payoneer Global Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PAYO | ZBH | |
|---|---|---|
Market Cap | $2.43B | $16.95B |
Volume | 1,342,701 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $7.18 | $103.98 |
52-Week Low | $4.27 | $79.58 |
Typical Hold Time | 61 Days | 89 Days |
Enterprise Value | $2.17B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.15, down slightly by 0.14% with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights Payoneer's renewed partnership with Etsy through 2029 and the company's agreement to be acquired by Nuvei announced in June 2026. Analyst sentiment remains positive with 60% buy ratings despite recent earnings volatility.
The acquisition by Nuvei creates near-term upside potential, but execution risks and margin compression pose challenges. Revenue growth remains solid at 15% volume growth year-over-year, though net income margin has declined from 16.8% in 2024 to 5.8% projected for 2026. The stock's valuation at 51x P/E appears stretched relative to earnings growth, suggesting cautious optimism is warranted.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
